Expert Perspectives on New Data in Multiple Sclerosis From the 2018 European MS Meeting

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Pregnancy and MS

Knowledge Gap Teratogenic Risks of DMTs

Reproductive Decision Making in MS

Reproductive Decision Making in MS (cont)

Reproductive History in a Danish Nationwide Study

Pregnancy Outcomes With Teriflunomide

Ocrelizumab and Pregnancy Outcomes

Concluding Remarks

Clinical Trial Data for Investigational Disease-Modifying Therapies for Relapsing MS

Ublituximab

Ublituximab in RRMS

Bruton Tyrosine Kinase Inhibitor

Evobrutinib Phase 2, 48-Week Study

Evobrutinib Safety Data

Cladribine Post-Hoc Analysis of CLARITY Data

Cladribine Post-Hoc Analysis of CLARITY Data (cont)

Practical Issues in Multiple Sclerosis

DMT Treatment Timing in RRMS

Predictors of Risk for Progression to SPMS

Comorbidities and MS

Acute Myocardial Infarction and MS

sNfL

Implementing sNfL Testing Into Practice

Long-Term Use of Disease-Modifying Therapies for Relapsing MS

Natalizumab, JCV, and PML

Natalizumab EID and Efficacy

Natalizumab EID and PML Risk

Saturation of CD49d With Natalizumab in EID

Alemtuzumab Long-Term Safety and Efficacy Data

Efficacy of Treatment Prospective 2-Year Study of Fingolimod and GA

Abbreviations

Abbreviations (cont)